InMed Pharmaceuticals (INM) said Tuesday that its INM-901 small molecule drug candidate for Alzheimer's disease reduced several plasma and brain markers of neuroinflammation in the trial.
The company said the study showed that INM-901 treated groups demonstrated a dose-dependent and statistically significant reduction in plasma pro-inflammatory cytokines and neurofilament light chain in the plasma for the high-dose treated group.
InMed also said the trial demonstrated a reduction of several key neuroinflammatory genes in the brain.
Shares of the company were up 43% in recent Tuesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。